Literature DB >> 23856388

Lorazepam-diazepam protocol for catatonia in schizophrenia: a 21-case analysis.

Chin-Chuen Lin1, Tiao-Lai Huang.   

Abstract

OBJECTIVES: Catatonia is a unique clinical phenomenon characterized by concurrent motor, emotional, vegetative and behavioral signs. Benzodiazepines (BZD) and electroconvulsive therapy (ECT) can rapidly relieve catatonic signs. The lorazepam-diazepam protocol presented here has been proven to relieve catatonia in schizophrenia within a day.
METHODS: From July 2002 to August 2011, schizophrenic patients requiring psychiatric intervention for catatonia in Kaohsiung Chang Gung Memorial Hospital were studied by medical chart review. The study used the Bush-Francis Catatonia Rating Scale (BFCRS). Patients receiving the lorazepam-diazepam protocol were identified.
RESULTS: The survey included 21 patients (eight males and 13 females) with a mean age of 30.3 ± 12.6 years. Mean duration of schizophrenia was 4.7 ± 5.6 years. Thirteen (61.9%) patients responded within 2 h, 18 (85.7%) responded within one day, and all became catatonia-free within a week. Mean BFCRS score was 9.9 ± 3.0 before treatment. Patients that responded with a single intramuscular lorazepam injection had mean BFCRS score of 8.9 ± 2.8, significantly lower than the mean score (11.6 ± 2.5) of the rest of the patients (p = 0.034).
CONCLUSIONS: The lorazepam-diazepam protocol can rapidly relieve retarded catatonia in schizophrenia. Most patients became catatonia-free within one day but some may require up to a week. ECT should be considered if the protocol fails.
© 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856388     DOI: 10.1016/j.comppsych.2013.06.003

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  9 in total

1.  The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry.

Authors:  Chin-Chuen Lin; Yi-Yung Hung; Meng-Chang Tsai; Tiao-Lai Huang
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

Review 2.  Systematic review of catatonia treatment.

Authors:  Anne Cm Pelzer; Frank Mma van der Heijden; Erik den Boer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-17       Impact factor: 2.570

3.  A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy.

Authors:  Yuanhan Bai; Xi Yang; Zhiqiang Zeng; Haichen Yang
Journal:  BMC Psychiatry       Date:  2018-03-13       Impact factor: 3.630

4.  Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients.

Authors:  Bunta Yoshimura; Tomoya Hirota; Manabu Takaki; Yoshiki Kishi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-10       Impact factor: 2.570

Review 5.  A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review.

Authors:  Yu-Jie Chiou; Yu Lee; Chin-Chuen Lin; Tiao-Lai Huang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

Review 6.  Neurobiological Approach of Catatonia and Treatment Perspectives.

Authors:  Pierre Ellul; Walid Choucha
Journal:  Front Psychiatry       Date:  2015-12-24       Impact factor: 4.157

7.  Increased serum anti-N-methyl-D-aspartate receptor antibody immunofluorescence in psychiatric patients with past catatonia.

Authors:  Chin-Chuen Lin; Yi-Yung Hung; Meng-Chang Tsai; Tiao-Lai Huang
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

8.  Excited catatonia in a patient with fatal pulmonary embolism and a successful treatment strategy.

Authors:  Wei-Ting Tseng; Tiao-Lai Huang
Journal:  BMC Psychiatry       Date:  2018-10-19       Impact factor: 3.630

9.  Diagnostic, Treatment, and System Challenges in the Management of Recurrent Neuroleptic Malignant Syndrome on a General Medical Service.

Authors:  Karan Verma; Vivek Jayadeva; Raymond Serrano; Karthik Sivashanker
Journal:  Case Rep Psychiatry       Date:  2018-06-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.